The PRESCIENT project, part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, focuses on predicting clinical outcomes in individuals at clinical high risk (CHR) for psychosis. The project aims to develop models that use clinical and biomarker data to predict a wide range of outcomes for these individuals. By analyzing this data, the project seeks to facilitate early identification of individuals most at risk of progressing to psychosis and to inform clinical trial participation and treatment strategies. https://www.ampscz.or